Antibiotic stewardship in burn care

Overview

Antibiotic stewardship in burn care is the systematic effort to optimize antimicrobial prescribing in a population that occupies an uncomfortable intersection: burn patients are profoundly immunosuppressed, chronically colonized, and exposed to more antibiotics per admission day than almost any other patient population. The consequence is that burn units serve as incubators for multidrug-resistant organisms (MDROs), and the decisions made about empiric therapy, de-escalation, and topical antimicrobial selection shape the resistance ecology of the entire unit.

Burn-specific sepsis definitions

The foundational framework for recognizing infection in burn patients was established by the ABA consensus conference, led by Greenhalgh et al. ^[1], which addressed the problem that standard sepsis criteria are baseline findings in major burns. The consensus defined burn-specific sepsis triggers and standardized definitions for wound infection, pneumonia, and UTI specific to the burn population. Without these burn-adapted definitions, antibiotic stewardship is impossible because the threshold for initiating therapy cannot be rationally set.

Peck et al. ^[4] proposed standardized surveillance definitions for burn wound infections, arguing that existing CDC nosocomial infection definitions were inadequate for burn patients. Standardized definitions are a prerequisite for stewardship because without consistent diagnostic criteria, antibiotic utilization cannot be benchmarked.

Wound flora ecology and empiric coverage

Pruitt et al. ^[2] established the classification of burn wound infections based on causative organism, depth of invasion, and tissue response, demonstrating that wound flora follow a predictable temporal pattern -- gram-positive organisms predominate early, followed by gram-negative colonization, followed by fungal species in prolonged open wounds. This ecology directly informs empiric coverage choices at different phases of care. Pruitt and McManus ^[3] further documented how topical chemotherapy, prompt excision, and timely wound closure reduced invasive infection, while emphasizing that surveillance cultures and biopsy monitoring should guide antimicrobial decisions rather than reflexive empiric escalation.

Resistance patterns and topical alternatives

Branski et al. ^[5] documented the global rise of multidrug-resistant S. aureus, Pseudomonas, Acinetobacter, and fungal pathogens, highlighting the urgent need for alternative treatment strategies as systemic options narrow.

A critical stewardship question is whether topical antimicrobials retain activity against organisms that have become resistant to systemic antibiotics. Neely et al. ^[7] tested 47 MDROs from four burn hospitals against 11 commonly used topical agents and found that most topical antimicrobials remained effective against systemically resistant organisms, though important exceptions existed. This finding supports the rational use of topical agents as a stewardship-aligned alternative to systemic therapy for wound colonization and superficial infection.

Strock et al. ^[8] demonstrated the efficacy of topical mupirocin against methicillin-resistant staphylococci in burn wounds, providing evidence for targeted topical therapy as an alternative to systemic vancomycin for superficial MRSA wound colonization. Barret et al. ^[9] reported on topical nystatin powder at high concentration for angioinvasive fungal infections refractory to other agents, illustrating both the severity of fungal resistance in burn patients and the role of topical alternatives when systemic options fail.

Greenhalgh ^[13] provided a strategic framework for rational topical antimicrobial use, emphasizing that the choice of agent should match the wound phase and clinical context -- superficial burns require agents that optimize re-epithelialization, while deep burns awaiting excision require agents that suppress microbial proliferation. This phase-based approach is itself a stewardship principle: matching intensity of antimicrobial intervention to clinical need.

Fungal diagnostics and antifungal stewardship

Dudoignon et al. ^[10] evaluated diagnostic criteria for invasive mold infections in severe burn patients, finding that current definitions are poorly adapted to this population. Their retrospective cohort of patients with 15% or greater TBSA burns demonstrated that refining diagnostic criteria improves the ability to distinguish colonization from invasion, which directly impacts antifungal stewardship -- the difference between prophylaxis, empiric therapy, and targeted treatment.

Infection prevention as stewardship

Palmieri ^[6] described how burn unit structure and design impact infection rates, noting that open wounds, hydrotherapy, and shared equipment create transmission opportunities not seen in other ICU settings. Environmental controls, ventilation design, and patient cohorting reduce selective pressure for resistance by reducing transmission events.

Aguilera-Saez et al. ^[11] described the management of an extensively drug-resistant Pseudomonas aeruginosa outbreak in a burn unit, detailing the combination of patient screening, environmental surveillance, cohorting, and targeted antimicrobial therapy required to contain the outbreak. Their experience underscores that stewardship and infection prevention are inseparable -- without containment, resistance spreads regardless of prescribing discipline.

Lee et al. ^[12] demonstrated that simplifying isolation technique while enforcing compliance reduced unit-acquired colonization from 63% to 33% and delayed Pseudomonas colonization from 7.8 to 21 days, simultaneously reducing costs. This finding argues that stewardship efforts must extend beyond prescribing to include the infection prevention infrastructure that determines microbial exposure.

Controversies and Evidence Gaps

The optimal duration of empiric antibiotic therapy in burn patients remains undefined. While general critical care has moved toward shorter courses guided by biomarkers like procalcitonin, the persistent inflammatory state in burns confounds these markers, and burn-specific data on safe de-escalation timelines are sparse. The role of antibiotic cycling -- rotating empiric regimens on a scheduled basis to reduce selection pressure -- has theoretical appeal but lacks convincing evidence of sustained benefit in burn units. The threshold for initiating empiric systemic antibiotics versus topical therapy alone for wound colonization with resistant organisms is a daily clinical decision without strong evidence to guide it. Finally, the emerging problem of invasive fungal disease in severely burned patients is complicated by diagnostic criteria that were not designed for this population, leading to both overtreatment and missed diagnoses.

References

[1] Greenhalgh DG et al. (2007). American Burn Association consensus conference to define sepsis and infection in burns. PMID: 17925660 [2] Pruitt BA et al. (1998). Burn wound infections: current status. PMID: 9451928 [3] Pruitt BA, McManus AT. (1992). The changing epidemiology of infection in burn patients. PMID: 1290268 [4] Peck MD et al. (1998). Surveillance of burn wound infections: a proposal for definitions. PMID: 9789171 [5] Branski LK et al. (2009). Emerging infections in burns. PMID: 19810827 [6] Palmieri TL. (2019). Infection Prevention: Unique Aspects of Burn Units. PMID: 30676249 [7] Neely AN et al. (2009). Are topical antimicrobials effective against bacteria that are highly resistant to systemic antibiotics? PMID: 19060725 [8] Strock LL et al. (1990). Topical Bactroban (mupirocin): efficacy in treating burn wounds infected with methicillin-resistant staphylococci. PMID: 2123203 [9] Barret JP et al. (1999). Topical nystatin powder in severe burns: a new treatment for angioinvasive fungal infections refractory to other topical and systemic agents. PMID: 10498358 [10] Dudoignon E et al. (2026). Characteristics of mycological criteria for the diagnosis of invasive mold infections in patients with severe burn injury. PMID: 41641958 [11] Aguilera-Saez J et al. (2019). Extensively drug-resistant Pseudomonas Aeruginosa outbreak in a burn unit: management and solutions. PMID: 31285735 [12] Lee JJ et al. (1990). Infection control in a burn center. PMID: 2286616 [13] Greenhalgh DG. (2009). Topical antimicrobial agents for burn wounds. PMID: 19793554